| Target Molecule | Thymosin Beta 4 (Tβ4) |
| Synonyms | Tβ4, Thymosin β4, Thymosin beta-4, FX-1004 |
| CAS Number | 77591-33-4 |
| Sequence (3-Letter) | Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH |
| Sequence (1-Letter) | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES |
| Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
| Molecular Weight | 4963.4 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate, TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) for Long-Chain Sequences |
| Modification Options | N-terminal acetylation, stable isotope labeling (13C, 15N), fluorescent/biotin tagging, Met-oxidation standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and extended regulatory documentation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Thymosin Beta 4 (Tβ4, CAS 77591-33-4) is an intrinsically disordered 43-amino acid peptide characterized by N-terminal acetylation. We target this sequence to supply high-purity reference materials and raw materials for regenerative medicine, wound healing assays, and actin-cytoskeletal research.
We utilize optimized solid-phase peptide synthesis (SPPS) protocols on low-loading resins. Because assembling a 43-residue chain carries significant risks of sequence truncation and aggregation, our peptide synthesis platform applies high-efficiency coupling reagents and continuous monitoring, coupled with inert gas cleavage to protect the Met6 residue.
Yes. We provide specialized peptide modification services for Thymosin Beta 4. Options include complete N-terminal acetylation, site-specific stable isotope labeling (13C, 15N) for quantitative LC-MS/MS, fluorescent and biotin tagging, and the synthesis of methionine sulfoxide impurity standards for stability-indicating assays.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (such as TFA removal to acetate) to ensure strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex preclinical pipelines.
Thymosin Beta 4 (Tβ4, CAS 77591-33-4) is an endogenously occurring 43-residue peptide defined by the N-terminally acetylated sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. Functioning as a primary G-actin-sequestering molecule in eukaryotic cells, it plays a vital role in tissue repair, cell migration, and cytoskeletal dynamics. Synpeptide provides comprehensive custom synthesis solutions for this molecule, showcasing our technical capabilities in long-chain assembly, capping chemistries, and CDMO manufacturing.
Synthesizing a 43-amino acid chain requires exceptional coupling efficiency across numerous sterically hindered junctions to prevent deletion sequences. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins. By deploying high-efficiency coupling reagents, temperature control, and complete N-terminal acetyl capping, we suppress truncated byproducts, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
The sequence of Thymosin Beta 4 contains a sensitive methionine residue at position 6 that is prone to oxidation, converting to methionine sulfoxide during handling. Through our peptide modification services, we protect vulnerable residues using inert atmosphere handling and customized cleavage scavenger systems. Furthermore, we synthesize defined methionine sulfoxide variants and truncated fragments as reference standards, and offer stable isotope labeling (13C, 15N) or fluorescent probes for pharmacokinetic tracking and binding studies.
Moving a 43-residue peptide from laboratory research to commercial scale demands robust chemical engineering during downstream chromatographic isolation. We execute large-scale peptide synthesis for Thymosin Beta 4 by optimizing fluid dynamics and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (including acetate conversion) and consistent lyophilization profiles across all production volumes.
We deliver integrated technical support as an established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream clinical-stage programs.
